Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
medicaid
8
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
8
×
wisconsin blog main
wisconsin top stories
national
biotech
medicare
clinical trials
deals
fda
johnson & johnson
biogen
cancer
eli lilly
nancy pelosi
sanofi
startups
trump administration
What
drug
roundup
alzheimer’s
bio
plan
price
house
prices
year
administration
aducanumab
agency
ahead
aimmune
allergy
ambien
american
amyloid
anathema
angry
angst
annual
answer
anti
approval
approved
asco
attendees
attention
awaited
awarded
away
bagged
benefited
billions
biogen
biogen’s
biotech
brammer
camp’s
Language
unset
Current search:
medicaid
×
" texas top stories "
×
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More